SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Politics for Pros- moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: greenspirit who wrote (708038)3/23/2020 10:15:08 AM
From: skinowski1 Recommendation

Recommended By
Sdgla

  Read Replies (2) of 793843
 
It’s a known thing that when one of the arms of a double blind study is clearly superior, the study gets stopped. No point in being stubborn and hurt people on the “losing side” of the trial.

There is a gray area in all this. The French doc had his trial formalized to some extent, it seems... but 3 dozed patients (I think he had) probably are still meaningless statistically. What Dr Grace does - and everyone else, too - simply using the medications off label - is anecdotal. But, when “anecdotal” data becomes clear and overwhelming - there ought to be a (formal) way of accepting it as valid.

Off label use of meds is legal - but the prescriber needs to have very good reasons behind the action. With off label use, the potential liability is much higher. Well, in the trenches, people still do what has to be done.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News